Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03288129
Other study ID # E2007-G000-410
Secondary ID 2017-001180-20
Status Completed
Phase Phase 4
First received
Last updated
Start date August 23, 2017
Est. completion date April 27, 2021

Study information

Verified date April 2022
Source Eisai Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the retention rate of perampanel when given as monotherapy or first adjunctive therapy in participants with partial-onset seizures or primary generalized tonic clonic seizures. The study consists of 4 periods: a Screening Period (to start no earlier than 6 weeks before the first dose of study drug), a Titration Period (up to 13 weeks), a Maintenance Period (39 weeks), and a Follow-Up Period (4 weeks).


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date April 27, 2021
Est. primary completion date April 27, 2021
Accepts healthy volunteers No
Gender All
Age group 4 Years and older
Eligibility Inclusion Criteria: - Participants will be male or female and no younger than 4 years of age and be able to swallow perampanel tablets. - Participants must have a diagnosis of epilepsy with POS with or without SGS or with PGTCS. Either of the following must have occurred to support an epilepsy diagnosis: 1. At least two unprovoked (or reflex) seizures occurring greater than 24 hours apart 2. One unprovoked (or reflex) seizure with Electroencephalography (EEG) evidence of seizures - Participants who receive perampanel as a first adjunctive therapy must currently have been treated with stable doses of monotherapy with an anti-epileptic drug (AED) for 8 weeks prior to Visit 2 (Week 0), have not previously received adjunctive AED treatment, and must, in the investigator's judgement, be in need of initial adjunctive therapy after failure to control seizures with AED monotherapy, at the optimal dose and duration. - Participants who receive perampanel as monotherapy, who were newly diagnosed (treatment naïve), following the defined diagnosis of epilepsy. - Participants who are currently receiving monotherapy treatment may receive perampanel as monotherapy if, in the investigator's judgment, the participant may benefit from a change in monotherapy treatment. Participants must not have previously received adjunctive AED treatment. - If antidepressants or antianxiety drugs are used, participants must be on a stable dose regimen of these drugs during the 8 weeks before Visit 2 (Week 0). Exclusion Criteria: - Participants should not have previously received or currently be receiving perampanel. - Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta human chorionic gonadotropin [ß-hCG] or hCG test with a minimum sensitivity of 25 International Units per liter [IU/L] or equivalent units of ß-hCG or hCG); a separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. - Females of childbearing potential who: - Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following: - Total abstinence (if it is their preferred and usual lifestyle) - An intrauterine device or intrauterine hormone-releasing system - An oral contraceptive (with additional barrier method if using contraceptive containing levonorgestrel); participant must be on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 28 days after study drug discontinuation - Have a vasectomized partner with confirmed azoospermia - Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation For sites outside of the European Union, it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, i.e, double barrier methods of contraception such as condom plus diaphragm or cervical/vault cap with spermicide. NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing). - Presence of or previous history of Lennox-Gastaut syndrome - Presence of non-motor simple partial seizures only - A history of status epilepticus within 1 year before Screening Visit (Visit 1) - Participants on antipsychotics or who have psychotic disorder(s) or unstable recurrent affective disorder(s) with a history of attempted suicide within 1 year before Screening Visit (Visit 1) - Presence of a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors - Concomitant use of barbiturates (except for seizure control indication and premedication for electroencephalogram) and benzodiazepines (except for seizure control indication) within 8 weeks prior to Visit 2 (Week 0) - Use of intermittent rescue benzodiazepines (i.e, 1 to 2 doses over a 24-hour period is considered a one time rescue) 2 or more times in the 8-week period prior to Visit 2 (Week 0) - Severe renal insufficiency (defined by estimated glomerular filtration rate of < 30 milliliters per minute [mL/min]) or participants who receive hemodialysis - Evidence of clinically significant disease (eg, cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the participant's safety or study conduct NOTE: Stable elevation of liver enzymes, alanine aminotransferase and aspartate aminotransferase due to concomitant medication(s) will be allowed if they are less than 3 times the upper limits of normal. - Hypersensitivity to perampanel or any excipients - Participants with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption - Participants who are participating in other interventional clinical trial - Participant who are judged to have inadequate cognitive ability for participation in the study (intelligence quotient < 80 or investigator judgment) - Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of screening, as indicated by answering "Yes" to questions 4 and 5 on the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (C-SSRS) - Any lifetime suicidal behavior based on the C-SSRS - Concomitant use of any form of cannabidiol (CBD) - Planned brain surgery during study participation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Perampanel
film-coated tablets

Locations

Country Name City State
United States UNM Health Providers Albuquerque New Mexico
United States The Regents of The University of Michigan Ann Arbor Michigan
United States Johns Hopkins Medicine Baltimore Maryland
United States Mid-Atlantic Epilepsy and Sleep Center Bethesda Maryland
United States The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham Birmingham Alabama
United States Tufts Medical Center Boston Massachusetts
United States RUSH University Medical Center Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States University Hospitals Cleveland Medical Center Cleveland Ohio
United States UT Southwestern Medical Center Dallas Texas
United States Duke Neurology Durham North Carolina
United States Michigan State University East Lansing Michigan
United States JFK Medical Center Edison New Jersey
United States Minneapolis Clinic of Neurology Golden Valley Minnesota
United States Northeast Regional Epilepsy Group Hackensack New Jersey
United States Baptist Health, Nemours Children's Specialty Care Jacksonville Florida
United States UCSD Epilepsy Center La Jolla California
United States University of Kentucky Lexington Kentucky
United States Arkansas Epilepsy Program Little Rock Arkansas
United States Mount Sinai Medical Center New York New York
United States Stanford Medical Center Palo Alto California
United States Barrow Neurological Institute Phoenix Arizona
United States UC Davis Medical Center Sacramento California
United States Children's Hospital of San Antonio San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Eisai Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment The retention rate was defined as the percentage of participants remaining on perampanel treatment at 3 months after the initiation of treatment. Month 3
Primary Percentage of Participants Remaining on Perampanel Treatment at 6 Months After the Initiation of Treatment The retention rate was defined as the percentage of participants remaining on perampanel treatment at 6 months after the initiation of treatment. Month 6
Primary Percentage of Participants Remaining on Perampanel Treatment at 9 Months After the Initiation of Treatment The retention rate was defined as the percentage of participants remaining on perampanel treatment at 9 months after the initiation of treatment. Month 9
Primary Percentage of Participants Remaining on Perampanel Treatment at 12 Months After the Initiation of Treatment The retention rate was defined as the percentage of participants remaining on perampanel treatment at 12 months after the initiation of treatment. Month 12
Secondary Percentage of Participants Who Achieved Seizure-free Status During the Maintenance Period Seizure-free status was defined as no incidence of seizure during the entire maintenance period. Partial seizures: when abnormal electrical activity begins in only one part of brain include (1) simple partial seizures: participants does not lose consciousness may experience muscle jerking or stiffening, (2) complex partial seizures: participant loses awareness. SGS: disturbances that spread to both sides of brain after partial seizure has already begun and happen when burst of electrical activity in limited area (the partial seizure) spreads throughout brain. PGTCS: disturbances in functioning of both sides of brain that caused by electrical signals spreading through brain inappropriately. Up to 39 weeks of Maintenance Period
Secondary Percentage of Participants Who Achieved 3-month Seizure-free Status During the Maintenance Period Seizure-free status was defined as no incidence of seizure at 3 months during the Maintenance Period. Partial seizures: when abnormal electrical activity begins in only one part of brain include (1) simple partial seizures: participant does not lose consciousness may experience muscle jerking or stiffening, (2) complex partial seizures: participant loses awareness. SGS: disturbances that spread to both sides of brain after partial seizure has already begun and happen when burst of electrical activity in limited area (the partial seizure) spreads throughout brain. PGTCS: disturbances in functioning of both sides of brain that caused by electrical signals spreading through brain inappropriately. Up to 3 months of Maintenance Period
Secondary Percentage of Participants Who Achieved 6-month Seizure-free Status During the Maintenance Period Seizure-free status was defined as no incidence of seizure at 6 months during Maintenance Period. Partial seizures: when abnormal electrical activity begins in only one part of brain include (1) simple partial seizures: participant does not lose consciousness may experience muscle jerking or stiffening, (2) complex partial seizures: participant loses awareness. SGS: disturbances that spread to both sides of brain after partial seizure has already begun and happen when burst of electrical activity in limited area (the partial seizure) spreads throughout brain. PGTCS: disturbances in functioning of both sides of brain that caused by electrical signals spreading through brain inappropriately. Up to 6 months of Maintenance Period
Secondary Percentage of Participants Who Received Perampanel as a First Adjunctive Therapy and Converted to Perampanel Monotherapy Percentage of participants who received perampanel as a first adjunctive therapy and converted to perampanel monotherapy were reported. Up to 52 weeks
Secondary Number of Participants With Treatment-emergent Adverse Events (TEAE) A TEAE was defined as an adverse event (AE) that emerged during treatment, having been absent at pretreatment (Baseline) or reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the AE was continuous. From date of first administration of study drug up to 28 days after last dose of study drug (up to 56 weeks)
Secondary Number of Participants With Treatment-emergent Serious Adverse Events (SAE) A SAE was defined as any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect. A TEAE was defined as an event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state. From date of first administration of study drug up to 28 days after last dose of study drug (up to 56 weeks)
See also
  Status Clinical Trial Phase
Completed NCT01710657 - A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures Phase 3
Completed NCT00975715 - Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures Phase 2/Phase 3
Completed NCT02072824 - A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures. Phase 3
Completed NCT01830868 - A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
Completed NCT03201900 - Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study) Phase 3
Completed NCT01338805 - Phase II BGG492 Capsule Extension for Partial Epilepsy Phase 2
Completed NCT01147003 - Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures Phase 2
Completed NCT01407523 - An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures Phase 2
Completed NCT04252846 - A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
Completed NCT01051193 - Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures Phase 2/Phase 3
Completed NCT03836924 - A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
Completed NCT01506882 - An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy Phase 3
Withdrawn NCT01167335 - Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures Phase 2
Completed NCT01830400 - A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS) N/A
Completed NCT00655551 - Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures Phase 3
Completed NCT00655486 - Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures Phase 3
No longer available NCT01871233 - An Extended Access Program for Perampanel